Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

A combination of providing clean needles and syringes and offering safer oral therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection.

Published
08 December 2017
From
National Institute for Health Research
MSF: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

Medecins Sans Frontieres (MSF) has begun treatment for hepatitis C with people who are co-infected with hepatitis C and HIV in Mykolaiv region, in southern Ukraine, where prevalence of HIV is two times higher than the average across the country.

Published
04 December 2017
From
UNIAN
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the US price: report

It was expected that Gilead would deeply discount Sovaldi for the Chinese market, but the reported price is still much higher than in other emerging markets where it has licensed the drug to generics makers.

Published
29 November 2017
From
FiercePharma
More work and lower drug prices are needed to eliminate hepatitis C worldwide

Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do this more people need to be tested and treated

Published
29 November 2017
By
Liz Highleyman
Sofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV)

Published
28 November 2017
By
Liz Highleyman
How Drug Users Would Solve the Opioid Crisis

Users say they want to end prohibition, seek reparations, and get invested in pain alternatives like weed. In Vancouver, that’s already happening.

Published
15 November 2017
From
Vice
Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid US outbreaks

Since March, the CDC’s Division of Viral Hepatitis has identified hepatitis A outbreaks in several cities in California, Michigan and Utah, especially among people who are homeless and people who use drugs. Over the past six months, those ongoing outbreaks have resulted in supply stress for vaccine makers Merck and GSK, which sell U.S.-licensed hepatitis A shots Vaqta and Havrix, respectively.

Published
15 November 2017
From
FiercePharma
Nivolumab improves outcomes in liver cancer study

Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumour size or disease stabilisation in people with hepatocellular

Published
14 November 2017
By
Liz Highleyman
Eliminating viral hepatitis: time to match visions with action

Fundamentally, the tools needed to move towards elimination targets already exist—an effective vaccine for hepatitis B and a curative treatment for hepatitis C. What is needed now more than anything else is the political will to scale up prevention, diagnosis, and treatment programmes.

Published
10 November 2017
From
The Lancet (editorial)
8 things to know ahead of the World Hepatitis Summit

Devex spoke with Gottfried Hirnschall and Marc Bulterys of the World Health Organization about the gaps, outstanding challenges, and ongoing work toward elimination. Here’s what you can expect from the three-day meeting.

Published
02 November 2017
From
Devex
← First12345...231Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.